Overview
Cerixen 150 mg contains Ceritinib, a highly potent and selective oral tyrosine kinase inhibitor (TKI) that specifically targets the Anaplastic Lymphoma Kinase (ALK) protein. Manufactured by Everest Pharmaceuticals Ltd. and supplied globally by Saif Pharma, Cerixen is an advanced oncology treatment designed for patients with Non-Small Cell Lung Cancer (NSCLC) driven by ALK gene alterations. Cerixen is engineered to overcome resistance seen with first-generation ALK inhibitors and features excellent blood-brain barrier penetration, making it highly effective against central nervous system (CNS) metastases.
Therapeutic Applications
Cerixen is primarily indicated for the treatment of:
First-Line ALK-Positive NSCLC: For adult patients with newly diagnosed, locally advanced or metastatic non-small cell lung cancer that is confirmed to be ALK-positive.
Subsequent-Line ALK-Positive NSCLC: For patients with metastatic ALK-positive NSCLC whose disease has progressed on or who are intolerant to first-generation ALK inhibitors (such as Crizotinib).
Brain Metastases: Used to manage and control secondary tumors that have spread to the brain from the primary lung cancer site.
Mechanism of Action
Ceritinib acts as an ATP-competitive, small-molecule inhibitor of ALK tyrosine kinase:
Signal Interruption: It binds tightly to the ALK receptor, blocking its autophosphorylation. This effectively shuts down the downstream signaling pathways—such as STAT3, AKT, and ERK—that tell cancer cells to grow and multiply.
Overcoming Resistance: Cerixen is highly effective against several mutated forms of the ALK protein that cause resistance to early-generation treatments.
Broad Spectrum Kinase Inhibition: Beyond ALK, Ceritinib also inhibits the insulin-like growth factor 1 receptor (IGF-1R), insulin receptor (InsR), and ROS1, providing multi-layered cellular control.
Pharmacokinetic Profile
Absorption: Reaches peak plasma concentrations ($T_{max}$) approximately 4 to 6 hours after oral dosing.
Bioavailability Buffer: Bioavailability increases significantly when taken with food, which is why current clinical protocols leverage low-dose administration with meals to reduce gastrointestinal side effects.
Metabolism: Extensively metabolized in the liver, primarily via the CYP3A enzyme system.
Elimination: Cleared mainly through feces (~92.3%), with a terminal elimination half-life averaging 31 to 41 hours, supporting steady once-daily scheduling.
Dosage & Administration
Standard Adult Dose: The standard recommended dose is 450 mg (three 15 mg tablets) taken orally once daily.
Food Instructions: Cerixen must be taken with food (a low-fat meal is preferred to improve absorption and minimize stomach upset).
Administration: Tablets must be swallowed whole with water. Do not crush, chew, split, or dissolve the tablets.
Missed Doses: If a dose is missed, it should only be taken if the next scheduled dose is more than 12 hours away. If the patient vomits, they should not take an additional dose; simply resume with the next scheduled daily dose.
Clinical Considerations & Safety
Gastrointestinal Toxicity: Diarrhea, nausea, vomiting, and abdominal pain are common. These symptoms are typically manageable with anti-emetics, anti-diarrheals, or temporary dose reductions.
Hepatotoxicity: Can cause elevations in liver enzymes (ALT/AST) and bilirubin. Liver function tests are required every 2 weeks during the first month and monthly thereafter.
QT Prolongation: Periodic monitoring of ECG and electrolytes (potassium, magnesium) is vital, especially in patients with pre-existing cardiac conditions.
Hyperglycemia: Blood glucose levels should be checked before starting treatment and monitored periodically, as Ceritinib can induce high blood sugar levels.
Pneumonitis/ILD: Severe, life-threatening interstitial lung disease can occur. Monitor for sudden breathing difficulties, cough, or fever.
Special Populations
Pregnancy & Lactation: Ceritinib can cause fetal harm. Effective contraception is required for female patients during treatment and for up to 6 months after the final dose. Breastfeeding is contraindicated.
Hepatic Impairment: Ceritinib is cleared by the liver. Patients with moderate-to-severe hepatic impairment require careful monitoring and a baseline dose adjustment.